PharmaCyte Biotech, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended April 30, 2019, compared with fiscal 2018. The request identifies “2018 Q4,” but this filing is an annual report for the year ended April 30, 2019, not a standalone quarterly report.
Business context
PharmaCyte is a clinical-stage biotechnology company with no commercial products or revenue. It is developing cell therapies using its licensed Cell-in-a-Box cellulose-based encapsulation technology. Its lead program targets locally advanced, inoperable pancreatic cancer (LAPC); other programs address cancer using cannabinoids, malignant ascites, and insulin-dependent diabetes.
Financial and operating metrics
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $4.10 million | $6.98 million |
| Research and development expense | $460,052 | $1.998 million |
| Net loss | $4.07 million | $6.83 million |
| Net loss per share, basic and diluted | $0.00, rounded | $0.01 |
| Cash used in operating activities | $2.88 million | $5.08 million |
| Cash provided by financing activities | $2.34 million | $2.68 million |
| Cash at year-end | $515,253 | $1.060 million |
| Current assets / current liabilities | $653,404 / $742,851 | $1.284 million / $644,168 |
FY 2019 gross margin is not meaningful because the company reported no revenue. Working capital was negative $89,447 at April 30, 2019, versus positive approximately $639,697 a year earlier. Total liabilities were $742,851; the filing reports no borrowings or debt balance. Accumulated deficit was $100.03 million. The company reported total assets of $5.78 million and stockholders’ equity of $5.04 million.
Changes versus the prior year
- Operating expenses fell by approximately $2.88 million, primarily due to lower R&D, compensation, and consulting expenses; lower stock-based compensation contributed to the reduced net loss.
- R&D expense declined 77% to $460,052. The filing attributes this to lower development spending during the period; this reduction should be considered alongside the work still required before the planned trial.
- Cash declined $544,545 during FY 2019, compared with a $2.40 million decrease in FY 2018. Financing continued to rely on common-stock sales.
- Shares outstanding increased from 1.013 billion to 1.186 billion at fiscal year-end. Subsequent to year-end, additional shares were sold, adding to potential dilution.
Outlook, risks, and unusual items
- Lead program: The company was preparing an IND submission to the FDA for a planned Phase 2b LAPC trial; the IND had not yet been submitted or approved. The proposed study is approximately 100 patients and compares CypCaps plus low-dose ifosfamide with specified chemoradiation approaches. Medpace was selected as the CRO. Clinical materials, testing, and regulatory documentation remained in preparation.
- Other programs: The company planned another preclinical study for malignant ascites. Diabetes development faced instability in the licensed Melligen cells; the company was pursuing cell redevelopment and alternative encapsulated stem-cell or islet-cell approaches. Cannabinoid work remained preclinical.
- Liquidity and going concern: The filing says substantial additional capital is required and describes substantial doubt about the company’s ability to continue as a going concern. Management believes financing plans—including further stock sales and stated commitments—can fund operations through July 31, 2020, assuming access to financing and continued eligibility to use its registration statement. Cash expenditures were approximately $240,000 per month at the time of the filing. There is no assurance the planned financing will be available on acceptable terms.
- Equity financing and dilution: From May 2018 through April 2019, the company reported approximately $2.5 million raised in block trades; its FY 2019 cash-flow statement reports $2.34 million net proceeds from common-stock sales. From May 1 through August 12, 2019, it sold 136.7 million shares for approximately $950,000 gross, with related fees and warrant coverage. These figures use different periods and gross/net bases.
- Licensing and related parties: May 2018 amendments eliminated specified milestone-payment obligations to SG Austria/Austrianova, revised certain royalties, and expanded the diabetes license scope. The company reported paying Austrianova the agreed $900,000 in full by April 30, 2019. Austrianova-related entities are also key suppliers and licensors; purchases of their products and services were approximately $168,000 in FY 2019, down from $1.389 million in FY 2018.
- Prior clinical evidence: Earlier European pancreatic-cancer trials were small, single-arm studies conducted in 1998–2000. The filing notes their results were not statistically significant and may not predict later outcomes; the FDA may not accept the historical data.
- Controls and audit: Management concluded disclosure controls and internal control over financial reporting were ineffective at April 30, 2019, citing weaknesses in control documentation and contract review, segregation of duties, and IT controls. The independent auditor issued an unqualified opinion on the financial statements but was not engaged to audit internal controls. Management warned that weaknesses could result in misstatement or restatement.
- The company reported no material pending litigation. It reported no revenue, product approvals, or profitability, and warned of clinical, regulatory, manufacturing, intellectual-property, third-party, financing, and stock-dilution risks.
Most important facts for investors to verify
- Whether and when the FDA receives and clears the IND, and whether the clinical product and manufacturing documentation satisfy regulatory requirements.
- Actual cash burn, financing commitments and proceeds, eligibility to continue registered offerings, and the company’s ability to fund operations beyond its stated runway.
- Progress and reproducibility of manufacturing runs, and whether Austrianova remains able to supply clinical material on time.
- Share-count changes, outstanding options and warrants, and the full dilution implications of further equity financing.
- Remediation of the disclosed internal-control weaknesses, including evidence that contract review, segregation of duties, and IT controls are operating effectively.